| Identification | Back Directory | [Name]
Benzamide, N-[[12-[4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-14-hydroxy-3,6,9-trioxa-12-azatetradec-1-yl]oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]- | [CAS]
2281803-33-4 | [Synonyms]
Benzamide, N-[[12-[4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-14-hydroxy-3,6,9-trioxa-12-azatetradec-1-yl]oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]- | [Molecular Formula]
C38H41F5IN9O7 | [MOL File]
2281803-33-4.mol | [Molecular Weight]
957.68 |
| Hazard Information | Back Directory | [Uses]
MEK/PI3K-IN-2 (compound 6s) is a potent MEK/PI3K inhibitor, with IC50 values of 352 nM (MEK1), 107 nM (PI3Kα), and 137 nM (PI3Kδ), respectively. MEK/PI3K-IN-2 suppresses pAKT and pERK1/2 levels. MEK/PI3K-IN-2 shows anti-proliferative activity against tumor cell lines[1]. | [IC 50]
MEK1: 352 ± 2 nM (IC50); PI3Kα: 107 ± 21 nM (IC50); PI3Kδ: 137 ± 7 nM (IC50); PI3Kγ: 2567 ± 364 nM (IC50); PI3Kβ: 3880 ± 725 nM (IC50) | [References]
[1] Van Dort ME, et al. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. Eur J Med Chem. 2022 Feb 5;229:113996. DOI:10.1016/j.ejmech.2021.113996 |
|
|